EXONDYS 51 Rx
Generic Name and Formulations:
Eteplirsen 50mg/mL; per vial; soln for IV infusion after dilution; preservative-free.
Indications for EXONDYS 51:
Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation that is amenable to exon 51 skipping.
Adults and Children:
May apply topical anesthetic cream to IV site prior to administration. Give by IV infusion over 35–60mins. 30mg/kg once weekly.
Treat appropriately and consider slowing the infusion or interrupting therapy if a hypersensitivity reaction occurs. Renal or hepatic impairment. Pregnancy. Nursing mothers.
Do not mix or infuse with other medications concomitantly via same IV access line.
Balance disorder, vomiting, contact dermatitis; hypersensitivity reactions.
Single-dose vial (2mL, 10mL)—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|